Bio-Path Holdings Inc

HOUSTON, April 19, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (Nasdaq: BPTH) (the “Company” or “Bio-Path”), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules of an aggregate of 375,000 shares of its common stock at a purchase price of $3.225 per share and concurrent private placement of unregistered warrants to purchase up to an aggregate of 375,000 shares of common stock. The warrants have an exercise price of $3.10 per share, are immediately exercisable and will expire five years from the date of issuance.

Related tickers: BPTH.

Bio-Path (BPTH) gains 30% on encouraging developmental updates from the early-stage study of its investigational candidate, BP1002, to treat acute myeloid leukemia patients.

Related tickers: BPTH, ADMA, FGEN, ANVS.